Lau M E, Hansen H H, Nissen N I, Pedersen H
Cancer Treat Rep. 1979 Mar;63(3):485-7.
A new oral form of VP-16-213 consisting of a hydrophilic soft gelatin capsule containing a VP-16-213 solution was tested for toxicity in 26 patients. The drug was administered at four different dose levels, 350, 500, 650, and 750 mg/m2, in 5-day courses every 21-28 days. A dose-dependent effect was observed with regard to hematologic toxicity and alopecia. It is concluded that the drinking ampules of VP-16-213 can be replaced with the new oral capsules with a recommended initial dose of 100-130 mg/m2 given in 5-day courses every 21-28 days.
一种新型口服制剂VP - 16 - 213，其为含有VP - 16 - 213溶液的亲水性软胶囊，对26例患者进行了毒性测试。药物以350、500、650和750mg/m²这四个不同剂量水平给药，每21 - 28天进行为期5天的疗程。观察到血液学毒性和脱发方面存在剂量依赖性效应。得出结论，VP - 16 - 213的口服液体制剂可用新型口服胶囊替代，推荐初始剂量为100 - 130mg/m²，每21 - 28天进行为期5天的疗程。
